NEWS
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Novavax has received Emergency Use Authorization (EUA) from the FDA for its 2024-2025 Formula COVID-19 Vaccine(NVX-CoV2705) for individuals aged 12 and older. The vaccine is included in the CDC's recommendations and will be available in pre-filled syringes at thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for COVID-19 prevention.
The updated vaccine targets the JN.1 variant, the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses. The EUA was based on non-clinical data demonstrating protection against JN.1 and its lineage viruses. Common adverse reactions include headache, nausea, muscle pain, and injection site tenderness.
Novavax has received Emergency Use Authorization (EUA) from the FDA for its 2024-2025 Formula COVID-19 Vaccine(NVX-CoV2705) for individuals aged 12 and older. The vaccine is included in the CDC's recommendations and will be available in pre-filled syringes at thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for COVID-19 prevention.
The updated vaccine targets the JN.1 variant, the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses. The EUA was based on non-clinical data demonstrating protection against JN.1 and its lineage viruses. Common adverse reactions include headache, nausea, muscle pain, and injection site tenderness.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment